In clinical trials, 12C79 (valerosol) was effective in increasing O2 affinity of Hb both in normal HbAA individuals [37] and SCD patients [38] but had a rather short half life. Although 589C80 (tucaresol) with its longer half life and ability to improve haematological parameters in sickle patients, side-effects included fever and cervical lymphadenopathy